Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Uncovering the Evidence Frontier Beyond the Lipid-Lowering Effects of PCSK9 Inhibitors in Heart Transplantation.

The American journal of the medical sciences·2026
Same author

Testing behavioral economics principles in mailed FIT outreach: a randomized trial.

Cancer causes & control : CCC·2026
Same author

Evidence-Based Frameworks Increase Engagement in Serious Illness Communication Conversations for Patients With Cirrhosis.

The American journal of hospice & palliative care·2026
Same author

Updated International Patient Decision Aid Standards (IPDAS version 5.0): modified Delphi, evidence informed consensus process.

BMJ (Clinical research ed.)·2026
Same author

Implementation of a Hospital-Based Screening and Treatment Program for Unhealthy Alcohol Use.

Journal of general internal medicine·2026
Same author

Factors Associated with Produce Prescription Program Enrollment and Benefit Use among Patients with Diabetes and at Risk for Food Insecurity.

The Journal of nutrition·2026

関連する実験動画

Updated: Jun 23, 2026

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

この患者は臨床的にうつ病ですか?

John W Williams1, Polly Hitchcock Noël, Jeffrey A Cordes

  • 1Department of Veterans Affairs Medical Center, 508 Fulton St, HSR&D, Bldg 6, Durham, NC 27705, USA. jw.williams@duke.edu

JAMA
|March 7, 2002
PubMed
まとめ

鬱病の正確な診断は,さまざまなアンケートと臨床面接を使用して可能です. これらのツールは,臨床医が信頼できる結果で重度のうつ病を特定するのに役立ちます.

科学分野:

  • 精神医学とメンタルヘルス
  • 診断精度に関する研究 診断精度に関する研究
  • プライマリーケア医療 プライマリーケア医療

背景:

  • うつ病は一般的ですが,明確な診断検査がないため,診断は困難です.
  • 効果的なスクリーニングと診断ツールは,うつ病の適切な介入と管理に不可欠です.

研究 の 目的:

  • 鬱病アンケートの診断の正確性と精度を体系的に検討する.
  • 重度のうつ病の診断における臨床検査の信頼性を評価する.
  • 様々なスクリーニング機器と診断方法の性能を比較する.

主な方法:

  • MEDLINEと専門登録簿を使用して,1970年から2000年にかけての英語研究に関する包括的な文献検索.
  • ケースファインディング研究 (≥100人のプライマリケア患者,検証されたアンケート) と信頼性研究 (≥2人の臨床医,基準に基づく診断) を含む.
  • 対象となる研究の厳格な品質評価,サンプルサイズ,患者選択,ブラインド,診断手順に焦点を当てた.

主要な成果:

  • 投与に1~5分かかる11件のうつ病アンケートでは,比較可能な性能特性を示した.
  • 重度のうつ病のポジティブな確率比は3.3で,ネガティブな確率比は0.19でした.

さらに関連する動画

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

関連する実験動画

Last Updated: Jun 23, 2026

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

  • 半構造面接を用いたメンタルヘルス専門家の間で,高いインターレーター信頼性 (kappa=0.64-0.93) が観察された;プライマリケア医師も高い合意を示した (kappa=0.71).
  • 結論:

    • 臨床医を支援するために,良好なパフォーマンスを有する多数の実用的なうつ病アンケートがあります.
    • 臨床面接,特に半構造面接は,精神保健の専門家または初等医療の医師によって実施され,信頼性の高い診断確認を提供します.
    • これらの検証済みのツールは,臨床環境における重度のうつ病障害の識別と診断を強化します.